Equillium Statistics
Total Valuation
Equillium has a market cap or net worth of $130.92 million. The enterprise value is $98.55 million.
Important Dates
The next estimated earnings date is Monday, March 23, 2026, before market open.
| Earnings Date | Mar 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Equillium has 60.89 million shares outstanding. The number of shares has increased by 22.17% in one year.
| Current Share Class | 62.07M |
| Shares Outstanding | 60.89M |
| Shares Change (YoY) | +22.17% |
| Shares Change (QoQ) | +82.88% |
| Owned by Insiders (%) | 11.10% |
| Owned by Institutions (%) | 27.91% |
| Float | 29.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.81 |
| Forward PS | n/a |
| PB Ratio | 4.22 |
| P/TBV Ratio | 4.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 22.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.85 |
| Quick Ratio | 10.74 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -90.24% and return on invested capital (ROIC) is -55.03%.
| Return on Equity (ROE) | -90.24% |
| Return on Assets (ROA) | -44.17% |
| Return on Invested Capital (ROIC) | -55.03% |
| Return on Capital Employed (ROCE) | -77.58% |
| Weighted Average Cost of Capital (WACC) | 14.22% |
| Revenue Per Employee | $125,486 |
| Profits Per Employee | -$697,629 |
| Employee Count | 35 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Equillium has paid $361,000 in taxes.
| Income Tax | 361,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +187.46% in the last 52 weeks. The beta is 1.83, so Equillium's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | +187.46% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 61.75 |
| Average Volume (20 Days) | 599,619 |
Short Selling Information
The latest short interest is 2.08 million, so 3.42% of the outstanding shares have been sold short.
| Short Interest | 2.08M |
| Short Previous Month | 1.97M |
| Short % of Shares Out | 3.42% |
| Short % of Float | 7.15% |
| Short Ratio (days to cover) | 4.37 |
Income Statement
In the last 12 months, Equillium had revenue of $4.39 million and -$24.42 million in losses. Loss per share was -$0.57.
| Revenue | 4.39M |
| Gross Profit | 4.39M |
| Operating Income | -24.37M |
| Pretax Income | -24.06M |
| Net Income | -24.42M |
| EBITDA | -24.24M |
| EBIT | -24.37M |
| Loss Per Share | -$0.57 |
Full Income StatementBalance Sheet
The company has $33.12 million in cash and $745,000 in debt, with a net cash position of $32.38 million or $0.53 per share.
| Cash & Cash Equivalents | 33.12M |
| Total Debt | 745,000 |
| Net Cash | 32.38M |
| Net Cash Per Share | $0.53 |
| Equity (Book Value) | 30.94M |
| Book Value Per Share | 0.51 |
| Working Capital | 30.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.91 million and capital expenditures -$8,000, giving a free cash flow of -$22.92 million.
| Operating Cash Flow | -22.91M |
| Capital Expenditures | -8,000 |
| Free Cash Flow | -22.92M |
| FCF Per Share | -$0.38 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -554.87% |
| Pretax Margin | -547.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Equillium does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.17% |
| Shareholder Yield | -22.17% |
| Earnings Yield | -18.65% |
| FCF Yield | -17.51% |
Analyst Forecast
The average price target for Equillium is $6.50, which is 202.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.50 |
| Price Target Difference | 202.33% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Equillium has an Altman Z-Score of -4.36 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.36 |
| Piotroski F-Score | 2 |
